Literature DB >> 32437779

Dual mechanisms suppress meloxicam bioactivation relative to sudoxicam.

Dustyn A Barnette1, Mary A Schleiff1, Laura R Osborn1, Noah Flynn2, Matthew Matlock2, S Joshua Swamidass2, Grover P Miller3.   

Abstract

Thiazoles are biologically active aromatic heterocyclic rings occurring frequently in natural products and drugs. These molecules undergo typically harmless elimination; however, a hepatotoxic response can occur due to multistep bioactivation of the thiazole to generate a reactive thioamide. A basis for those differences in outcomes remains unknown. A textbook example is the high hepatotoxicity observed for sudoxicam in contrast to the relative safe use and marketability of meloxicam, which differs in structure from sudoxicam by the addition of a single methyl group. Both drugs undergo bioactivation, but meloxicam exhibits an additional detoxification pathway due to hydroxylation of the methyl group. We hypothesized that thiazole bioactivation efficiency is similar between sudoxicam and meloxicam due to the methyl group being a weak electron donator, and thus, the relevance of bioactivation depends on the competing detoxification pathway. For a rapid analysis, we modeled epoxidation of sudoxicam derivatives to investigate the impact of substituents on thiazole bioactivation. As expected, electron donating groups increased the likelihood for epoxidation with a minimal effect for the methyl group, but model predictions did not extrapolate well among all types of substituents. Through analytical methods, we measured steady-state kinetics for metabolic bioactivation of sudoxicam and meloxicam by human liver microsomes. Sudoxicam bioactivation was 6-fold more efficient than that for meloxicam, yet meloxicam showed a 6-fold higher efficiency of detoxification than bioactivation. Overall, sudoxicam bioactivation was 15-fold more likely than meloxicam considering all metabolic clearance pathways. Kinetic differences likely arise from different enzymes catalyzing respective metabolic pathways based on phenotyping studies. Rather than simply providing an alternative detoxification pathway, the meloxicam methyl group suppressed the bioactivation reaction. These findings indicate the impact of thiazole substituents on bioactivation is more complex than previously thought and likely contributes to the unpredictability of their toxic potential.
Copyright © 2020. Published by Elsevier B.V.

Entities:  

Keywords:  Bioactivation; Kinetics; Liver toxicity; Meloxicam; Sudoxicam; Thiazole

Mesh:

Substances:

Year:  2020        PMID: 32437779      PMCID: PMC8716319          DOI: 10.1016/j.tox.2020.152478

Source DB:  PubMed          Journal:  Toxicology        ISSN: 0300-483X            Impact factor:   4.221


  36 in total

Review 1.  Recent applications of 1,3-thiazole core structure in the identification of new lead compounds and drug discovery.

Authors:  Adile Ayati; Saeed Emami; Ali Asadipour; Abbas Shafiee; Alireza Foroumadi
Journal:  Eur J Med Chem       Date:  2015-04-13       Impact factor: 6.514

2.  Designing drugs to avoid toxicity.

Authors:  Graham F Smith
Journal:  Prog Med Chem       Date:  2011

3.  Effects of organic solvents on the activities of cytochrome P450 isoforms, UDP-dependent glucuronyl transferase, and phenol sulfotransferase in human hepatocytes.

Authors:  J Easterbrook; C Lu; Y Sakai; A P Li
Journal:  Drug Metab Dispos       Date:  2001-02       Impact factor: 3.922

4.  A simple model predicts UGT-mediated metabolism.

Authors:  Na Le Dang; Tyler B Hughes; Varun Krishnamurthy; S Joshua Swamidass
Journal:  Bioinformatics       Date:  2016-06-20       Impact factor: 6.937

5.  Anti-inflammatory and pharmacokinetic properties of sudoxicam N-(2-thiazolyl)-4-hydroxy-2-methyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide.

Authors:  E H Wiseman; J Chiaini
Journal:  Biochem Pharmacol       Date:  1972-09-01       Impact factor: 5.858

6.  Bioactivation of substituted thiophenes including α-chlorothiophene-containing compounds in human liver microsomes.

Authors:  Weiqi Chen; Janet Caceres-Cortes; Haiying Zhang; Donglu Zhang; W Griffith Humphreys; Jinping Gan
Journal:  Chem Res Toxicol       Date:  2011-04-13       Impact factor: 3.739

Review 7.  Heterotropic cooperativity in oxidation mediated by cytochrome p450.

Authors:  Toshiro Niwa; Norie Murayama; Hiroshi Yamazaki
Journal:  Curr Drug Metab       Date:  2008-06       Impact factor: 3.731

8.  Pharmacokinetics and metabolic pattern after intravenous infusion and oral administration to healthy subjects.

Authors:  J Schmid; U Busch; G Heinzel; G Bozler; S Kaschke; M Kummer
Journal:  Drug Metab Dispos       Date:  1995-11       Impact factor: 3.922

9.  EH3 (ABHD9): the first member of a new epoxide hydrolase family with high activity for fatty acid epoxides.

Authors:  Martina Decker; Magdalena Adamska; Annette Cronin; Francesca Di Giallonardo; Julia Burgener; Anne Marowsky; John R Falck; Christophe Morisseau; Bruce D Hammock; Artiom Gruzdev; Darryl C Zeldin; Michael Arand
Journal:  J Lipid Res       Date:  2012-07-12       Impact factor: 5.922

10.  Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction.

Authors:  Koji Sasaki; Amit Lahoti; Elias Jabbour; Preetesh Jain; Sherry Pierce; Gautam Borthakur; Naval Daver; Tapan Kadia; Naveen Pemmaraju; Alessandra Ferrajoli; Susan O'Brien; Hagop Kantarjian; Jorge Cortes
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2015-12-18
View more
  7 in total

1.  CYP2C9 and 3A4 play opposing roles in bioactivation and detoxification of diphenylamine NSAIDs.

Authors:  Mary Alexandra Schleiff; Samantha Crosby; Madison Blue; Benjamin Mark Schleiff; Gunnar Boysen; Grover Paul Miller
Journal:  Biochem Pharmacol       Date:  2021-11-05       Impact factor: 5.858

2.  Importance of substituents in ring opening: a DFT study on a model reaction of thiazole to thioamide.

Authors:  Xue Bai; Dan Qin; Lijun Yang
Journal:  J Mol Model       Date:  2021-02-21       Impact factor: 1.810

3.  Meloxicam methyl group determines enzyme specificity for thiazole bioactivation compared to sudoxicam.

Authors:  Dustyn A Barnette; Mary A Schleiff; Arghya Datta; Noah Flynn; S Joshua Swamidass; Grover P Miller
Journal:  Toxicol Lett       Date:  2020-11-27       Impact factor: 4.372

4.  Impacts of diphenylamine NSAID halogenation on bioactivation risks.

Authors:  Mary Alexandra Schleiff; Sasin Payakachat; Benjamin Mark Schleiff; S Joshua Swamidass; Gunnar Boysen; Grover Paul Miller
Journal:  Toxicology       Date:  2021-06-06       Impact factor: 4.571

5.  Significance of Multiple Bioactivation Pathways for Meclofenamate as Revealed through Modeling and Reaction Kinetics.

Authors:  Mary Alexandra Schleiff; Noah R Flynn; Sasin Payakachat; Benjamin Mark Schleiff; Anna O Pinson; Dennis W Province; S Joshua Swamidass; Gunnar Boysen; Grover P Miller
Journal:  Drug Metab Dispos       Date:  2020-11-25       Impact factor: 3.922

6.  Bioactivation of Isoxazole-Containing Bromodomain and Extra-Terminal Domain (BET) Inhibitors.

Authors:  Noah R Flynn; Michael D Ward; Mary A Schleiff; Corentine M C Laurin; Rohit Farmer; Stuart J Conway; Gunnar Boysen; S Joshua Swamidass; Grover P Miller
Journal:  Metabolites       Date:  2021-06-15

Review 7.  Monooxygenase- and Dioxygenase-Catalyzed Oxidative Dearomatization of Thiophenes by Sulfoxidation, cis-Dihydroxylation and Epoxidation.

Authors:  Derek R Boyd; Narain D Sharma; Paul J Stevenson; Patrick Hoering; Christopher C R Allen; Patrick M Dansette
Journal:  Int J Mol Sci       Date:  2022-01-14       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.